scispace - formally typeset
G

Gayathri R. Devi

Researcher at Duke University

Publications -  108
Citations -  4647

Gayathri R. Devi is an academic researcher from Duke University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 36, co-authored 97 publications receiving 3935 citations. Previous affiliations of Gayathri R. Devi include Beth Israel Deaconess Medical Center & Durham University.

Papers
More filters
Journal ArticleDOI

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model

TL;DR: This review attempts to summarize the various 3D culture systems, with an emphasis on the most well characterized and widely applied model - multicellular tumor spheroids.
Journal ArticleDOI

siRNA-based approaches in cancer therapy.

TL;DR: This paper summarizes the advances in the last decade in the field of PTGS using RNA interference approaches and provides relevant comparisons with other oligonucleotide-based approaches with a specific focus on oncology applications.
Journal ArticleDOI

Toward understanding cancer stem cell heterogeneity in the tumor microenvironment.

TL;DR: A mechanism-based dynamical model is shown that the diffusion of EMT-inducing signals such as TGF-β, together with noncell autonomous control of E MT and CSC decision making via the Notch signaling pathway, can explain experimentally observed disparate localization of subsets of CSCs with varying EMT phenotypes in the tumor.
Journal ArticleDOI

Modulation of Murine Breast Tumor Vascularity, Hypoxia, and Chemotherapeutic Response by Exercise

TL;DR: Exercise statistically significantly reduced tumor growth and was associated with a 1.4-fold increase in apoptosis in mice randomly assigned to exercise or sedentary control; exercise plus chemotherapy prolonged growth delay compared with chemotherapy alone (P < .001) in the orthotopic 4T1 model.
Journal ArticleDOI

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

TL;DR: Results indicate that IBC tumors are highly redox adapted, which may render them resistant to ROS‐inducing therapies, and DSF, through redox modulation, may be a useful approach to enhance chemo‐ and/or radio‐sensitivity for advanced BC subtypes where therapeutic resistance is an impediment to durable responses to current standard of care.